Modern approaches to the treatment of psychosomatic disorders associated with chronic dermatoses: a review

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Most contemporary studies indicate a high prevalence of psychosomatic disorders in patients with dermatological conditions.

This article presents a systematic scientific data review of therapeutic approaches to psychosomatic disorders associated with chronic dermatoses. The review summarizes data from various studies analyzing psychosomatic aspects of psoriasis, acne, alopecia, lichen planus, and vitiligo, including stress-induced mechanisms of their development and progression, the impact of stigmatization on patients’ psycho-emotional state, as well as quality of life. Particular attention is given to nosogenic (secondary) and comorbid psychiatric disorders associated with the underlying dermatological condition, such as anxiety–depressive disorders, social phobia, and hypochondriacal reactions. The rationale for implementing comprehensive therapeutic strategies has been substantiated, including psychopharmacological interventions (selective serotonin reuptake inhibitors, atypical antipsychotics, anxiolytics), cognitive behavioral therapy, and psychoeducational programs. Multidisciplinary approaches to patient management are considered, integrating dermatological treatment with psychotherapeutic and psychopharmacological methods aimed at improving patients’ adaptation. The article also provides updated information on the treatment of chronic dermatoses.

The scientific data search was conducted in national and international scientific databases (PubMed, Scopus, MedLine, Embase, Cochrane, Russian State Library, Central Scientific Medical Library of I.M. Sechenov First Moscow State Medical University).

According to the scientific data analysis, psychosomatic disorders comorbid with dermatological diseases require timely detection and treatment. Modern approaches to the treatment of psychosomatic disorders associated with skin diseases involve comprehensive therapy encompassing both dermatological care and psychocorrectional components (psychotherapy and psychopharmacotherapy). Social support also plays an important role. The competent use of psychocorrectional methods in combination with traditional dermatological therapy significantly enhances overall treatment efficacy, improves patients’ quality of life, and reduces the frequency of exacerbations of chronic dermatoses.

作者简介

Ekaterina Melnik

The First Sechenov Moscow State Medical University (Sechenov University)

编辑信件的主要联系方式.
Email: katerina.melnik.5@gmail.com
ORCID iD: 0000-0002-2500-7861
SPIN 代码: 7418-1995
俄罗斯联邦, 4/1 Bolshaya Pirogovskaya st, Moscow, 119991

Igor Dorozhenok

The First Sechenov Moscow State Medical University (Sechenov University); Scientific Center for Mental Health

Email: idoro@bk.ru
ORCID iD: 0000-0003-1613-2510
SPIN 代码: 8701-7958

MD, Cand. Sci. (Medicine), Assistant Professor

俄罗斯联邦, 4/1 Bolshaya Pirogovskaya st, Moscow, 119991; Moscow

Lyailya Kayumova

The First Sechenov Moscow State Medical University (Sechenov University)

Email: avestohka2005@inbox.ru
ORCID iD: 0000-0003-0301-737X
SPIN 代码: 4391-9553

MD, Cand. Sci. (Medicine), Assistant Professor

俄罗斯联邦, 4/1 Bolshaya Pirogovskaya st, Moscow, 119991

Konstantin Lomonosov

The First Sechenov Moscow State Medical University (Sechenov University)

Email: lamclinic@yandex.ru
ORCID iD: 0000-0002-4580-6193
SPIN 代码: 4784-9730

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, 4/1 Bolshaya Pirogovskaya st, Moscow, 119991

参考

  1. Siddiqui Z, Felder E, Hernandez K, et al. The psychosocial impact of pediatric vitiligo, psoriasis, eczema, and alopecia: a systematic review. Bull Menninger Clin. 2024;88(4):297–319. doi: 10.1521/bumc.2024.88.4.297 EDN: FRXXVH
  2. Dorozhenok IYu. Nosogenic psychosomatic disorders in patients with skin diseases. S.S. Korsakov J Neurol Psychiatry. 2023;123(4-2):36–43. doi: 10.17116/jnevro202312304236 EDN: XRNRCE
  3. Liu L, Lin NX, Yu YT, et al. Epidemiology of mental health comorbidity in patients with psoriasis: an analysis of trends from 1986 to 2019. Psychiatry Res. 2023;321:115078. doi: 10.1016/j.psychres.2023.115078 EDN: MDGJSY
  4. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–991. doi: 10.1038/jid.2014.530 EDN: UFQAAN
  5. Bechman K, Hayes JF, Mathewman J, et al. Electronic screening for mental illness in patients with psoriasis. Br J Dermatol. 2023;189(2):246–248. doi: 10.1093/bjd/ljad141 EDN: MKVQVE
  6. Chen Y, Sun S, Yang H, et al. Global prevalence of mental health comorbidity in patients with acne: an analysis of trends from 1961 to 2023. Clin Exp Dermatol. 2025;50(6):1083–1093. doi: 10.1093/ced/llae531 EDN: ZTVBCK
  7. Molla A, Alrizqi H, Alharbi E, et al. Assessment of anxiety and depression in patients with acne vulgaris in medina: a case-control study. Clin Cosmet Investig Dermatol. 2021;14:999–1007. doi: 10.2147/CCID.S302311 EDN: XXIBVR
  8. Lauron S, Plasse C, Vaysset M, et al. Prevalence and odds of depressive and anxiety disorders and symptoms in children and adults with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2023;159(3):281–288. doi: 10.1001/jamadermatol.2022.6085 EDN: NHZZSH
  9. Cai XC, Wang SH, Wang CX, et al. Epidemiology of mental health comorbidity in patients with atopic dermatitis: an analysis of global trends from 1998 to 2022. J Eur Acad Dermatol Venereol. 2024;38(3):496–512. doi: 10.1111/jdv.19686 EDN: JABAZG
  10. Jalenques I, Lauron S, Almon S, et al. Prevalence and odds of signs of depression and anxiety in patients with lichen planus: systematic review and meta-analyses. Acta Derm Venereol. 2020;100(18):adv00330. doi: 10.2340/00015555-3660 EDN: JEOHLI
  11. Lai YC, Yew YW, Kennedy C, Schwartz RA. Vitiligo and depression: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2017;177(3):708–718. doi: 10.1111/bjd.15199
  12. Alzeer FA, Alajlan A, Alshammari SA, et al. Depression and quality of life among Saudi patients with vitiligo: a descriptive quantitative review. Open Dermatol J. 2023;17:1–10. doi: 10.2174/18743722-v17-e230907-2023-5
  13. Kussainova A, Kassym L, Akhmetova A, et al. Vitiligo and anxiety: a systematic review and meta-analysis. PLoS One. 2020;15(11):e0241445. doi: 10.1371/journal.pone.0241445 EDN: EITTTZ
  14. Nasser MA, El Tahlawi SM, Abdelfatah ZA, Soltan M. Stress, anxiety, and depression in patients with vitiligo. Middle East Curr Psychiatry. 2021;28(1):28–63. doi: 10.1186/s43045-021-00120-w EDN: VVCCSC
  15. Li V, Frasier K, Woolhiser E, et al. Exploring the intersection of body dysmorphic disorder (BDD) and dermatological conditions: a narrative review. Dermatol Ther (Heidelb). 2024;14(10):2693–2708. doi: 10.1007/s13555-024-01256-3 EDN: ATPMYL
  16. Lönndahl L, Abdelhadi S, Holst M, et al. Psychological stress and atopic dermatitis: a focus group study. Ann Dermatol. 2023;35(5):342–347. doi: 10.5021/ad.22.035 EDN: DNZLIP
  17. Dorozhenok IYu, Snarskaya ES, Mikhailova M. Lichen planus and itch-related psychosomatic disorders. Russ J Skin Venereal Dis. 2021;24(6):543–551. doi: 10.17816/dv100612 EDN: WAOGSN
  18. Efanova EN, Vasilyeva EA, Kobylyanskaya NV, Kalinin MA. Analysis of the DLQI quality of life index (The Dermatology Life Quality Index) in patients with various dermatological nosologies. J Scientific Articles Health Education XXI Century. 2019;21(6):22–26. doi: 10.26787/nydha-2226-7425-2019-21-6-22-26 EDN: CGCEII
  19. Johns JR, Vyas J, Ali FM, et al. The Dermatology Life Quality Index as the primary outcome in randomized clinical trials: a systematic review. Br J Dermatol. 2024;191(4):497–507. doi: 10.1093/bjd/ljae228 EDN: APTKYD
  20. Hepat A, Chakole S, Rannaware A. Psychological well-being of adult psoriasis patients: a narrative review. Cureus. 2023;15(4):e37702. doi: 10.7759/cureus.37702 EDN: ZLJVFJ
  21. Blackstone B, Patel R, Bewley A. Assessing and improving psychological well-being in psoriasis: considerations for the clinician. Psoriasis (Auckl). 2022;12:25–33. doi: 10.2147/PTT.S328447 EDN: PIXTBY
  22. Nowowiejska J, Baran A, Grabowska P, et al. Assessment of life quality, stress and physical activity among patients with psoriasis. Dermatol Ther (Heidelb). 2022;12(2):395–406. doi: 10.1007/s13555-021-00662-1 EDN: XHZERG
  23. Haddad A, Zisman D. Comorbidities in patients with psoriatic arthritis. Rambam Maimonides Med J. 2017;8(1):e0004. doi: 10.5041/RMMJ.10279
  24. Soliman MM. Depressive, anxiety, stress, and insomnia symptoms in patients with psoriasis: a crosssectional study. Adv Dermatol Allergol. 2021;38(3):510–519. doi: 10.5114/ada.2020.98726 EDN: ISJOZR
  25. Lakshmy S, Balasundaram S, Sarkar S, et al. A cross-sectional study of prevalence and implications of depression and anxiety in psoriasis. Indian J Psychol Med. 2015;37(4):434–440. doi: 10.4103/0253-7176.168587 EDN: WRESCV
  26. López-Mejía R, Ramales-Montes EM, Ley-Silva LS, et al. Quality of life, depression and its relation to the severity in psoriasis. (In Spanish). Rev Med Inst Mex Seguro Soc. 2022;60(3):315–320.
  27. Schmitt J, Ford DE. Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis--a structural equations modeling approach. Gen Hosp Psychiatry. 2007;29(2):134–140. doi: 10.1016/j.genhosppsych.2006.12.004
  28. Dorozhenok IYu, Ilina EV. Psychosomatic aspects of psoriasis (review). Russ J Skin Venereal Dis. 2021;24(3):251–262. doi: 10.17816/dv71927 EDN: GWOWHT
  29. Alpsoy E, Ozcan E, Cetin L, et al. Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? A double-blind, placebo-controlled study. J Am Acad Dermatol. 1998;38(2 Pt 1):197–200. doi: 10.1016/s0190-9622(98)70240-3
  30. Sukharev AV, Patrushev AV, Nazarov RN, Gutka VO. Opportunites of applying new generation antidepressants for correction of psychosomatic disorders upon chronic dermatoses. Effective pharmacotherapy. 2014;19:18–23. EDN: SYTZDP
  31. Potekaev NN, Lvov AN, Zhukova OV, et al. Psychosomatic disorders and quality of life in patients with chronic facial dermatoses and their dynamics with underlying application of medical camouflage. Russ J Clin Dermatol Venereol. 2017;16(5):58–72. doi: 10.17116/klinderma201716558-71 EDN: ZTSVCT
  32. Smulevich AB, Dorozhenok IYu, Romanov DV, Lvov AN. Psychopathology of mental disorders in a dermatological clinic (a model of mental pathology limited by the space of the skin). In: A.B. Smulevich, ed. Psychosomatic disorders in clinical practice. Moscow; 2014. P. 350–373. (In Russ.)
  33. Il’chevskaya EA, Krinitsyna YM, Sergeeva IG. Abnormalities of psycho-emotional state among patients with excoriated acne. Vestnik dermatologii i venerologii. 2017;(5):64–69. doi: 10.25208/0042-4609-2017-93-5-64-69 EDN: ZXVUZF
  34. Volkova NV, Glazkova LK, Retyunsky KY. Diagnostic and treatment algorithm including psychiatric comorbidity of acne vulgaris patients. Ural Med J. 2013;(8):103–110. EDN: RSUODH
  35. Romanova YuYu, Romanov DV, Brazhnikov АYu, et al. Perspective targets for secondary prevention of quality of life decrease and psychosomatic disorders in alopecia: results of an observational study. Russ J Preventive Medicine. 2019;22(5):104–111. doi: 10.17116/profmed201922051104 EDN: NKDMCL
  36. Michenko AB, Lvov AN, Ivanov OL, et al. Psychosomatic aspects of atopic dermatitis: classical canons and new ideas. Russ J Skin Venereal Dis. 2008;(4):11–17. EDN: JUYRGN
  37. Potekaev NN, Danilin I, Korsunskaya I, et al. Atopic dermatitis: psychosomatic aspects. Vrach. 2018;29(2):18–21. doi: 10.29296/25877305-2018-02-04 EDN: YRVECH
  38. Fiocco Z, Kupf S, Patzak L, et al. Quality of life and psychopathology in lichen planus: a neglected disease burden. Acta Derm Venereol. 2021;101(12):adv00619. doi: 10.2340/actadv.v101.442 EDN: XJPREW
  39. Arnold S, Fernando S, Rees S. Living with vulval lichen sclerosus: a qualitative interview study. Br J Dermatol. 2022;187(6):909–918. doi: 10.1111/bjd.21777
  40. Nasimi M, Ahangari N, Lajevardi V, et al. The quality of life and mental health status in patients with lichen planopilaris based on dermatology life quality index and general health questionnaire-28 questionnaires. Int J Womens Dermatol. 2020;6(5):399–403. doi: 10.1016/j.ijwd.2020.09.005 EDN: EOOTGU
  41. Perlamutrov YuN, Olkhovskaya KB, Vasilenko TI, Anokhina DI. Lichenoid dermatoses of the anogenital area. Russ J Clin Dermatol Venereol. 2022;21(5):646–654. doi: 10.17116/klinderma202221051646 EDN: CRHNFI
  42. Adamo D, Calabria E, Coppola N, et al. Psychological profile and unexpected pain in oral lichen planus: a case-control multicenter SIPMO studya. Oral Dis. 20221;28(2):398–414. doi: 10.1111/odi.13787 EDN: XSWSEI
  43. Tlish MM, Osmolovskaya PS. Optimization of therapy in patients with lichen ruber planus by means of cranial electrotherapy stimulation. Almanac Clin Med. 2021;49(8):516–524. doi: 10.18786/2072-0505-2021-49-046 EDN: VNOZBH
  44. Gaitán-Cepeda LA, Rivera-Reza DI, Villanueva-Vilchis MD. Neuroticism and psychological stress in patients suffering oral lichen planus: research evidence of psycho-stomatology? Healthcare. 2023;11(12):1738. doi: 10.3390/healthcare11121738 EDN: QXSZHY
  45. Dorozhenok IYu, Snarskaya ES, Shenberg VG. Comorbid mental disorders in patients with lichen planus. Russ J Skin Venereal Dis. 2015;18(5):38–42. doi: 10.17816/dv36997 EDN: UXLNCF
  46. Bibeau K, Ezzedine K, Harris JE, et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo. JAMA Dermatology. 2023;159(10):1124. doi: 10.1001/jamadermatol.2023.2787 EDN: GRZPWS
  47. Zhang Y, Cai Y, Shi M, et al. The prevalence of vitiligo: a meta-analysis. PLoS One. 2016;11(9):e0163806. doi: 10.1371/journal.pone.0163806
  48. Naldi L, Pagani A, Alduini C. Vitiligo: epidemiology and economic impact. Dermatol Pract Concept. 2023;13(4S2):e2023315S. doi: 10.5826/dpc.1304S2a315S EDN: UMXUWQ
  49. Picardo M, Huggins RH, Jones H, et al. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J Eur Acad Dermatol Venereol. 2022;36(9):1507–1523. doi: 10.1111/jdv.18129 EDN: DWCWBB
  50. Augustin M, Gewiss C, Ben-Anaya N, Quality of life, disease burden and healthcare need of patients with vitiligo. Dermatologie (Heidelb). 2024;75(5):404–411. (In German). doi: 10.1007/s00105-024-05312-z EDN: CJTGWP
  51. Morrison B, Burden-Teh E, Batchelor JM, et al. Quality of life in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2017;177(6):e338–e339. doi: 10.1111/bjd.15933
  52. Cupertino F, Niemeyer-Corbellini JP, Ramos-E-Silva M. Psychosomatic aspects of vitiligo. Clin Dermatol. 2017;35(3):292–297. doi: 10.1016/j.clindermatol.2017.01.001
  53. Alharbi MA. Identifying patients at higher risk of depression among patients with vitiligo at outpatient setting. Mater Sociomed. 2020;32(2):108–111. doi: 10.5455/msm.2020.32.108-111 EDN: KOTJTO
  54. Al-Janabi MA, Dorozhenok IYu, Lomonosov KM. Psychosomatic aspects of vitiligo. A review of the literature. Russ J Skin Venereal Dis. 2023;26(6):597–603. doi: 10.17816/dv487099 EDN: TTYMWQ
  55. Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol. 2018;57(10):1157–1164. doi: 10.1111/ijd.14055
  56. Bonotis K, Pantelis K, Karaoulanis S, et al. Investigation of factors associated with health-related quality of life and psychological distress in vitiligo. J Dtsch Dermatol Ges. 2016;14(1):45–49. doi: 10.1111/ddg.12729
  57. Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial effects of vitiligo: a systematic literature review. Am J Clin Dermatol. 2021;22(6):757–774. doi: 10.1007/s40257-021-00631-6 EDN: KPNZQI
  58. Sarkar S, Sarkar T, Sarkar A, Das S. Vitiligo and psychiatric morbidity: a profile from a vitiligo clinic of a rural-based tertiary care center of Eastern India. Indian J Dermatology. 2018;63(4):281–284. doi: 10.4103/ijd.IJD_142_18
  59. Osinubi O, Grainge MJ, Hong L, et al. The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2018;178(4):863–878. doi: 10.1111/bjd.16049
  60. Carniciu S, Ha B, Gkini MA, et al. Secondary psychiatric disorders and the skin. Dermatological Rev. 2023;4(4):162–171. doi: 10.1002/der2.211
  61. Hamidizadeh N, Ranjbar S, Ghanizadeh A, et al. Evaluating prevalence of depression, anxiety and hopelessness in patients with Vitiligo on an Iranian population. Health Qual Life Outcomes. 2020;18(1):20. doi: 10.1186/s12955-020-1278-7 EDN: AGYLAM
  62. Wang KY, Wang KH, Zhang ZP. Health related quality of life and marital quality of vitiligo patients in China. J Eur Acad Dermatol Venereol. 2011;25(4):429–435. doi: 10.1111/j.1468-3083.2010.03808x
  63. Catucci Boza J, Giongo N, Machado P, et al. Quality of life impairment in children and adults with vitiligo: a cross-sectional study based on dermatology-specific and discase specific quality of life instruments. Dermatology. 2016;232(5):619–625. doi: 10.1159/000448656
  64. Dertlioglu SB, Cicek D, Balci DD, Halisdemir N. Dermatology life quality index scores in children with vitiligo: comparison with atopic dermatitis and healthy control subjects. Int J Dermatol. 2013;52(1):96–101. doi: 10.1111/j.1365-4632.2012.05616x
  65. Krüger C, Panske A, Schallreuter KU. Discase-related behavioral patterns and experiences affect quality of life in children and adolescents with vitiligo. Int J Dermatol. 2014;53(1):43–50. doi: 10.1111/j.1365-4632.2012.05656x
  66. Linthorst Homan MW, de Korte J, Grootenhuis MA, et al. Impact of childhood vitiligo on adult life. Br J Dermatol. 2008;159(4):915–920. doi: 10.1111/j.1365-2133.2008.08788.x
  67. Varzhapetyan AA, Dorozhenok IYu, Lomonosov KM. Vitiligo and comorbid psychosomatic disordes. Russ J Skin Venereal Dis. 2019;22(1-2):33–38. EDN: BATEUP
  68. Davletshina AYu, Lomonosov KM. Prospective methods of vitiligo treatment (literature review). Russ J Skin Venereal Dis. 2019;22(1-2):56–60. EDN: XCTBYD
  69. Koshevenko YN. Vitiligo: clinic, etiology, pathogenesis, treatment, rehabilitation, prevention. Moscow: Kosmetika i meditsina; 2002. Р. 492–500. (In Russ.)

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-Vector, 2025

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».